Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Senior Director, Finance | January 30, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDRA Life Sciences Inc.
Report date January 30, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.02 · Expires 2033-01-30 | Direct | 8,000 |
Reported balance
After 2023-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-30 · Grant · Acquired 8,000 · Balance 8,000 F1: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2023 Filed Feb 2, 2023 01:30 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 8,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-23-006048 · doc4.xml · derivative · entry 1 Pestrikova Irina · CIK 0001868216 · Senior Director, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-01-30 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 21:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 41,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-021620 · doc4.xml · derivative · entry 1 Pestrikova Irina · CIK 0001868216 · Senior Director, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2032-03-28 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 20:12 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-042378 · doc4.xml · derivative · entry 1 Pestrikova Irina · CIK 0001868216 · Senior Director, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning June 18, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.